Active ingredientAlmonertinibCat. No. P-A087-001CAS 1899921-05-1Family · Pharmaceutical analytical standards
Almonertinib
An oral inhibitor of the EGFR receptor for non-small cell lung cancer with EGFR mutations, also active against the T790M resistance mutation; approved in China in 2020 and in the European Union in 2026. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?At the time of its Chinese approval it was called almonertinib; today it is known mainly as aumolertinib, the name under which it was authorised in Europe.
Go to the active ingredient →Active ingredientAlmonertinibCat. No. P-A087-001CAS 1899921-05-1
Active ingredientAlmonertinib Mesylate SaltCat. No. P-A087-002CAS 2134096-06-1
Isotopically labelledAlmonertinib-d6Cat. No. P-A087-003
ImpurityAlmonertinib Impurity 1Cat. No. P-A087-004CAS 1899922-04-3No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.